18H0.F PreveCeutical Medical Inc
- Market cap
- EUR 5.74M
- P/E
- -
- P/B
- 22.23x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 18H0.F undervalued?
Graham numberThe Graham number of PreveCeutical Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PreveCeutical Medical Inc fundamental analysis
No fundamental analysis for PreveCeutical Medical Inc yet.
PreveCeutical Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PreveCeutical Medical Inc
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its research and development of preventive and therapeutic products derived from organic and nature-identical compounds; synthesized Nature Identical; Sol-Gel Nose-to-Brain delivery platform for Parkinson's disease; develops cannabinoid-based nose-to-brain delivery system for the relief of a variou…
Full company profilePreveCeutical Medical Inc financial statements
PreveCeutical Medical Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -898K | -1.06M | -963K | -812K | -3.37M |
| EBITDA | - | -1.23M | -955K | -837K | -1.35M |
| Net Income | -1.73M | -1.48M | -1.27M | -1.17M | -1.69M |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 161K | 189K | 182K | 226K | 1.45M |
| Total Liabilities | 4.27M | 4.82M | 5.96M | 6.86M | 7.69M |
| Shareholders' Equity | -4.10M | -4.64M | -5.78M | -6.64M | -6.24M |
| Cash & Short-term Investments | 16.1K | 5.62K | 1.43K | 59.1K | 10.2K |
| Cash Flow | |||||
| Operating Cash Flow | -426K | -223K | -297K | -427K | -1.72M |
| Capital Expenditure | 55.2K | 0.00 | 0.00 | 1.80K | 2.96K |
| Free Cash Flow | -482K | -223K | -297K | -428K | -1.72M |
| Ratios | |||||
| ROA | -1,071.1% | -783.2% | -702.1% | -520.5% | -116.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
PreveCeutical Medical Inc dividends
PreveCeutical Medical Inc has not paid dividends in the last 5 fiscal years.
Last stock split: 5:1 on May 23, 2018.
Who owns PreveCeutical Medical Inc
- Insiders 14.17%
- Institutions 0.00%
- Public & others 85.83%
- Shares outstanding 638M
- Free float 490M
PreveCeutical Medical Inc company profile
- Company name
- PreveCeutical Medical Inc
- Ticker
- 18H0.F
- ISIN
- CA74143C1068
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 5428 Marine Drive, West Vancouver, BC, Canada, V7W 2R2
- Phone
- 604 416 7777
- Website
- preveceutical.com
About PreveCeutical Medical Inc
PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its research and development of preventive and therapeutic products derived from organic and nature-identical compounds; synthesized Nature Identical; Sol-Gel Nose-to-Brain delivery platform for Parkinson's disease; develops cannabinoid-based nose-to-brain delivery system for the relief of a various ailments, including pain, inflammation, seizures, and neurological disorders; peptide library synthesis, pharmacological evaluation, alongside pharmacokinetic assessment, and determinations in animal models of pain and inflammation; and non-addictive analgesic peptides for pain management. It also involved in licensing, branding, and marketing nutraceutical and wellness products; Sol-Gel platform; and peptide program. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.
PreveCeutical Medical Inc management
4- Mr. Stephen Van DeventerChairman, CEO & CFO · born 1969
- Dr. Makarand Jawadekar Ph.D.Chief Science Officer, President & Director · born 1951
- Dr. Harendra Parekh BSc., Hons I, MRPharmS, Ph.D.Chief Research Officer
- Dr. Francis TavaresChief Technology Officer